Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs
Lan Juan Li,Wei Bo Du,Yi Min Zhang,Jun Li,Xiao Ping Pan,Jia Jia Chen,Hong Cui Cao,Yu Chen,Yue Mei Chen
DOI: https://doi.org/10.1016/j.jhep.2005.08.006
IF: 25.7
2006-01-01
Journal of Hepatology
Abstract:Methods FHF was induced with intravenous administration of D -galactosamine (1.3 g/kg) in each pig. Twelve hours post D -galactosamine injection, fifteen pigs were divided into: a BAL group ( n =5), in which pigs received the BAL treatment with 1.0 to 1.3×10 9 hepatocytes for 6 h, a sham BAL group ( n =5), in which pigs received the BAL treatment without hepatocytes, and a FHF group ( n =5), in which pigs only received intensive care. Parameters related to liver function and animal survival up to 168 h were determined. Results In the BAL group, blood ammonia and plasma lactate levels were lower, and serum glucose levels and Fischer index were higher than those in the other two groups. Survival time of pigs in the BAL group was significantly prolonged as compared with the sham BAL and the FHF group. Conclusions The BAL based on a nonwoven fabric bioreactor containing porcine hepatocytes appears to be effective in the treatment of FHF in pigs. Keywords Hepatic failure Bioartificial liver Hepatocyte Bioreactor Nonwoven fabric D -galactosamine Pig 1 Introduction Despite recent considerable improvements in supportive therapy, fulminant hepatic failure (FHF) remains a dramatic disease which is associated with a high mortality rate [1–3] . Orthotopic liver transplantation is the ultimate treatment for FHF [4–9] . However, numerous patients died while waiting for a transplant due to persistent scarcity of donors [10,11] . In such a situation, a bioartificial liver (BAL) may improve survival by bridging patients to liver transplantation or to regeneration of their diseased livers [12–17] . Currently, several BAL systems based on hollow fiber technology have been in various stages of clinical trials and proved to have some efficacy [18–26] . In each design, hepatocytes are inoculated into extracapillary space, either alone or attached to microcarriers, oxygenized plasma flows through the fiber lumina. Since the oxygen-binding ability of plasma is less than one-tenth that of whole blood, the oxygen supply to hepatocytes in these systems is far short of demand [27–29] . This problem leads to poor hepatocyte activity and insufficient hepatic function, thereby decreasing the efficiency of these devices [30] . To address the issue of adequate oxygenation of hepatocytes, we developed a novel BAL system which is based on a direct hemoperfusion typed nonwoven fabric (NWF) bioreactor containing porcine hepatocytes. In this study, we evaluated the efficacy of our BAL system using a D -galactosamine induced FHF in pigs. 2 Materials and methods The study protocol was approved by the Research, Animal Sources, and Animal Care committee, Zhejiang University and met institutional and national guidelines. 2.1 Animals Adult male Chinese experimental miniature pigs (5–10 kg) were purchased from Beijing Agriculture University. Adult male Buloc breeding pigs (20–25 kg) were purchased from Academy of Agriculture Science of Zhejiang Province. All pigs were housed in singular standard cages in an air-conditioned room (21–25 °C), with a 12 h light/dark cycle. Standard laboratory chow and water were given ad libitum. 2.2 Isolation of porcine hepatocytes Hepatocytes were isolated from Chinese experimental miniature pigs using a modified four-step collagenase perfusion method as described elsewhere [31] . Firstly, excised liver lobes were perfused at 37 °C with 300 ml and then at 39 °C with 500 ml of perfusion buffer solution (PBS) composed of 9 g/L NaCl, 0.42 g/L KCl, 2.1 g/L NaHCO 3 , 0.9 g/L glucose and 4.78 g/L Hepes (Sigma-Aldrich Inc., USA) containing 0.37 g/L of EDTA (Gibco, USA). Secondly, the liver lobes were perfused at 39 °C with 500 ml of PBS and 500 ml of PBS containing 8.4 g/L of dispase (Roche Ltd., Switzerland). Thirdly, the liver lobes were perfused with 500 ml of PBS containing 0.5 g/L of collagenase II (Invitrogen Corp., USA) and 0.275 g/L of CaCl 2 ·2H 2 O. The capsula of the liver lobes was then opened and digested parenchyma was collected on ice after filtration through 80-mesh of filter. Finally, the cells were washed three times with ice-cold washing buffer solution (WBS) composed of 7.0 g/L NaCl, 0.461 g/L KCl, 0.13 g/L CaCl 2 ·2H 2 O, 2.38 g/L Hepes and 1.0 g/L BSA (Gibco, USA) through centrifugation at 4 °C and 50× g for 2 min, followed by washing two times with WBS containing 1 g/L of DNase (Gibco, USA) through centrifugation at 4 °C and 50× g for 75 s. The cells were resuspended in DMEM culture media (Gibco, USA) and stored in ice-cool space. The yield varied from 1.2 to 1.5×10 7 hepatocytes per gram of wet liver weight, with viability ranging from 90 to 99%, as determined by trypan blue exclusion test. 2.3 Induction of FHF FHF was induced in Buloc breeding pigs with intravenous administration of D -galactosamine (Sigma-Aldrich Inc., USA) as described elsewhere [32] . Briefly, after a 6 h fasting, anesthesia was achieved with intramuscular administration of Ketamine (4 mg/kg), muscle relaxation was obtained with intravenous administration of Vecuronium Bromide (2 mg/kg). With sterile techniques, two 16-gauge catheters were placed in the right carotid artery and jugular vein, respectively. Animals were then allowed to wake up and to move freely in cages. Twenty-four hours after the cannulation, D -galactosamine was administrated intravenously to unanesthetized pigs at a dose of 1.3 g/kg body weight. Before injection, D -galactosamine was dissolved in 150 ml of 5% dextrose in water and adjusted to pH 6.8 with 1 N NaOH, then used within 2 h. 2.4 BAL system The BAL system consisted of a roller pump, a heparin pump, and an NWF-bioreactor (obtained from Kuraray Medical, Japan) which was placed in an incubator keeping an internal temperature of 37 °C ( Fig. 1 ). The volume of the entire system was approximately 120 ml. The NWF-bioreactor was designed with 500 polysulfone-based hollow fibers, which were spirally wound with nonwoven fabric polytetrafluoroethylene ( Fig. 2 ). The three-dimensional nonwoven fabric provides matrix which allows for hepatocytes immobilization and aggregation at high density (5×10 7 cells/ml). The semipermeable membrane of hollow fibers serves as exchangers and immuno-protective barriers, whole blood flows through the intra-luminal space of hollow fibers into direct contact with hepatocytes for effective oxygen supply, CO 2 removal and material exchange, thereby reducing the diffusion distance and allowing mass exchange similar to the situation in the sinusoids of the liver parenchyma. 2.5 Groups Fifteen FHF pigs were divided into: a BAL group ( n =5), in which pigs received the BAL treatment with hepatocytes, a sham BAL group (device control, n =5), in which pigs received the BAL treatment without hepatocytes, and a FHF group (control, n =5), in which pigs only received intensive care for establishing the basic parameters of the FHF model. 2.6 BAL procedure BAL treatment initiated at 12 h post D -galactosamine administration. Continued anesthesia was achieved by intravenous administration of Diprivan (AstraZeneca, Italy) at a dose of 10 mg/kg h. Pigs in the BAL and the sham BAL group were connected to the BAL device. Twenty milliliters of DMEM medium containing 1.0–1.3×10 9 porcine hepatocytes was inoculated into the NWF-bioreactor, and whole blood perfused through the intra-luminal space at a rate of 40 mL/min for a duration of 6 h. Heparin (100 U/kg) was administered intravenously at the start of treatment and continued at a dose of 40 U/kg h into the circuit, and removed 30 min before the end of the treatment. 2.7 Parameters Blood samples were collected for measurement of hemoglobin, platelet, prothrombin time (PT), ammonia, amino acid, creatinine, blood urea nitrogen, total bilirubin, bile acid, aspartate aminotransferase (AST), glucose and lactate, etc. Animal survival was measured up to 168 h to compare survival between three groups. 2.8 Statistics Values are presented as mean±SD. Statistical analysis was performed using a one-way ANOVA and t -test. Survival time was analyzed using the Kaplan–Meier method, and significance was tested with the log-rank test. A two-tailed P value <0.05 was considered significant. All data were analyzed with SPSS software (11.0). 3 Results 3.1 Clinical course and neurological status All pigs tolerated the BAL treatment well. No obvious coagulation was observed in the treatment period. After the BAL treatment, pigs awoke, stood, ate and drank freely. All pigs except two in the BAL group subsequently developed grade IV hepatic encephalopathy. The onset of hepatic encephalopathy was significantly delayed in the BAL group (61±8 h) as compared with both control groups (FHF group: 44±6 h; sham BAL group: 40±8 h, P <0.05). 3.2 Survival All pigs died, except two in the BAL group, and these were sacrificed 90 days later. Survival time ( Fig. 3 ) was significantly prolonged in the BAL group (106±23 h) as compared with both control groups (FHF group: 48±7 h; sham BAL group: 43±8 h, P <0.05). Survival time between both control groups was not significantly different ( P >0.05). 3.3 Biochemistry parameters As Fig. 4 shows, all pigs showed marked increases in PT, plasma ammonia and lactate acid levels, and a significant decrease in plasma glucose levels 12 h post D -galactosamine administration. In the BAL group, the plasma ammonia levels significantly decreased from 163.00±15.65 to 139.80±13.97 μmol/L during the BAL treatment ( P =0.01). Contrarily, the plasma ammonia levels in the FHF and the sham BAL groups significantly increased and reached 198.80±21.44 and 189.40±23.03 μmol/L, respectively. No significant difference in plasma ammonia levels between both control groups was observed ( P >0.05). The plasma glucose levels in all groups decreased during the treatment, since no supply of glucose in the study. However, significantly higher levels of glucose were seen in the BAL group as compared with both control groups at the end of the BAL treatment ( P <0.05). The serum lactate levels in the BAL group decreased markedly from 6.22±1.28 to 2.80±0.72 mmol/L, the post-BAL serum lactate levels in the BAL group was lower than that in both control groups ( P <0.01). PT in all groups was prolonged in the BAL treatment period. However, it was shorter in the BAL group (20.52±2.96 s) than that in the sham BAL group (25.14±2.93 s) at the end of BAL treatment ( P <0.05). Table 1 lists other parameters related to liver and kidney functions. The levels of AST, total bilirubin, bile acid gradually increased during the BAL treatment, showing no statistical differences between three groups. However, Fischer index significantly increased in the BAL group as compared with both control groups ( P <0.05). 3.4 Hepatocytes viability When the BAL treatment terminated, the NWF-bioreactors were perfused with 0.25% trypsinase, and hepatocytes were collected through centrifugation after washing with PBS three times. The hepatocytes viability varied between 75 and 79%, as determined by trypan blue exclusion test. 4 Discussion BAL is anticipated to be an effective treatment of choice for patients with FHF. For achieving better efficacy, most efforts have been contributed to the configurations of bioreactors for the purpose of in vitro mimicking the three dimensional microstructure of liver sinusoid, thereby maintaining viable functional hepatocytes outside of the body. Studies demonstrated that BAL systems based on hollow fiber bioreactors, for example, the HepatAssist system [28] and the Extracorporeal Liver Assist Device (ELAD) [27] , suffer from oxygen substrate limitations. In these systems, a large proportion of hepatocytes may be anoxic and lose their functions under typical operating conditions. Gerlach et al. [33] reported use of their own system which utilized a more sophisticated bioreactor, and demonstrated its efficacy in anhepatic pigs. This bioreactor consists of three bundles of interwoven capillaries that create a three-dimensional extracapillary space which provides an optimized compartment for hepatocytes attachment and reorganized into aggregates. However, the Gerlach bioreactor is too complex to run [17] . Another promising bioreactor design with an integral oxygenator was developed by Chamuleau and his colleagues [34] . Their bioreactor uses a spirally wound nonwoven polyester matrix which provides a three-dimensional structure for hepatocyte attachment, and integrated hollow-fiber membranes for oxygen supply. This design creates an environment that is more amenable to the optimal maintenance of hepatocytes, enabling them to retain their functions. The major disadvantage of the Chamuleau system is the direct contact between plasma and porcine liver cells. Consequently, there is no barrier for porcine pathogens. Moreover, no evidence demonstrated the efficacy of the internal oxygenator through direct comparison to similar bioreactor designs without an internal membrane oxygenator. Our BAL system is based on a direct hemoperfusion typed NWF-bioreactor. The bioreactor incorporates a spirally wound polyester matrix sheet that includes an integral hollow-fiber compartment for whole blood perfusion. At a certain extent, the configuration of our bioreactor is similar to the Chamuleau bioreactor. However, our bioreactor has no oxygenation capillaries, therefore, adequate oxygenation via whole blood instead of oxygenized plasma maybe sufficient to the hepatocytes during the in vivo application. Moreover, most of the hepatocytes attached to the surface of nonwoven fabric, only one membrane between the hepatocytes and the blood permits efficient material exchange. For a preclinical trial, a large clinically relevant animal model of FHF with high mortality as well as the potential for recovery is required [35] . Animal model of FHF induced by surgical methods, including hepatectomy and ischemic models, seems not suitable for testing the efficacy of a BAL device because they lack potential reversibility. Studies demonstrated that D -galactosamine induced FHF model possessed high reproducibility and potential reversibility, which met the majority of the criteria set by Terblanche and Hickman [32,36] . Moreover, this kind of animal model is morphologically similar to virus- or drug-related hepatic failure in human beings, as it is associated with neurological deterioration, hypoglycemia and death from liver failure [37–39] . In this study, we first established an FHF model in pigs by the administration of a rather high dose of D -galactosamine. The progression of FHF in pigs is reflected principally as rapid increases in plasma ammonia, serum bilirubin, AST, lactate acid levels, marked decreases in plasma glucose levels and Fischer index as well as significant prolongation in PT. These disturbances demonstrated that the cause of death in pigs was due to FHF. An effective BAL system should be capable of temporarily providing the deintoxication and synthesis functions of liver. In this study, pigs in both control groups appeared with dramatically decreased glucose levels, since no special efforts to normalize glucose concentration were performed during the BAL treatment. Contrarily, 6 h BAL treatment could maintain the plasma glucose concentration. In addition, a rapid decrease in serum lactate acid levels could be seen at the end of the BAL treatment. Normalized plasma glucose levels and decreased serum lactate levels indicated that hepatocytes in the NWF-bioreactors had exerted beneficial metabolic effects on the FHF pigs. Accumulation of plasma ammonia and aromatic amino acid is associated with the development of encephalopathy in FHF [40] . In addition, studies in vivo demonstrate that ammonia exerts an inhibitive effect on liver regeneration in animal models [41,42] . Thus the levels of ammonia and Fischer index are always used to evaluate the BAL system's effects in animal and clinical tests. In this study, the BAL group showed marked beneficial effects on ammonia levels compared with both control groups. Decreased ammonia levels during the BAL treatment indicated that our BAL system carried out positive ammonia removal function. Furthermore, the difference in Fischer index was found to be significant in the BAL group than that in both control groups. This indicated that 6 h BAL treatment also has a high compensatory capacity for regulating and maintaining the serum amino acid balance of FHF pigs. Progressing hepatic failure is also associated with coagulopathy, which manifests as a prolongation of PT and decrease in platelet count. In this study, no significant reduction of the PT in the BAL group was observed, this maybe duo to the administration of heparin during the BAL treatment. However, PT in the BAL group was shorter than that in the sham BAL group. This indicated that porcine hepatocytes in the NWF-bioreactor did synthesize some of the vitamin K-dependent clotting factors, which is consistent with studies by Patzer et al. [43] . However, the decreased platelet was not improved by the BAL treatment. Animal survival is usually considered as a definitive index for accessing the effects of a BAL system [44–47] . In a controlled study, dogs with ischemic liver failure treated with the HepatAssist incorporated with 5×10 9 matrix-attached hepatocytes showed significant neurological and biochemical improvements, but life was not prolonged [48,49] . However, treatment of ischemic pigs with the Chamuleau system which housing 1.4×10 10 porcine hepatocytes significantly increased survival time in association with a significant decrease in blood ammonia [50] . In this study, 6 h BAL treatment significantly prolonged animal survival time. This indicated that porcine hepatocytes in the NWF-bioreactor had exerted beneficial effects on animal survival. A recent study indicated that at lest 10 10 viable hepatocytes in a BAL bioreactor would be needed to support a patient's failing liver [51] . In this study, 10 9 hepatocytes were seeded at high density in a NWF bioreactor, although the population of hepatocytes was far from those in the Chamuleau system [50] and HepatAssist system [49] , our data suggested that the performance of our system maybe equal to the Chamuleau system, and probably superior to that of the HepatAssist system. Moreover, our bioreactor is easier to scale up by increasing the quantity of hollow fibers and the circles of wound nonwoven fabric, without losing the advantage of adequate oxygen supply, because each hollow fiber shared in theory the same portion of whole blood from the inlet of the cartridge. Although it is well known that hepatocytes dedifferentiate in vitro, the study demonstrated that uncultured porcine hepatocytes fully attached to the bioreactor within 2 h and were metabolically functional within 4 h [52] . Additionally, freshly isolated porcine hepatocytes loading inside the bioreactor allowed for the maintaining of liver cell differentiated functions [52] . Our results demonstrated that hepatocyes in the NWF-bioreactor still keep a high viability rate at the end of the treatment, possibly due to the bioreactor being perfused with whole blood instead of plasma. This suggested that the duration of the BAL treatment period could be further prolonged. Regarding the origin of hepatocytes, human hepatocytes are obviously the optimal choice for the BAL system. However, the limited availability of donor liver makes their use less feasible. Porcine hepatocytes are considered to be the best alternative to human hepatocytes for BAL because of anatomical and physiological similarities to human hepatocytes [48] . The major concern in the use of porcine hepatocytes is the risk of transfection of porcine endogenous retroviruses to the human population and severe immunological complications [53,54] , despite that no direct evidence of such a transfection has been observed in in vivo studies [55,56] . The gradual rise of serum aminotransferases, total bilirubin, and bile acid in the FHF pigs indicated that the 6 h BAL treatment may be insufficient to eliminate these accumulated materials. From the changes in hemoglobin value, leukocytes and platelet number, no severe damages were observed to exert on pig blood by the direct hemoperfusion through the BAL system. 5 Conclusion We therefore conclude that the BAL based on a direct hemoperfusion typed NWF-bioreactor with porcine hepatocytes appears to be effective in the treatment of FHF in pigs, with a prolonged survival time. The safety and efficacy of this novel system seems to be promising for human clinical care. Acknowledgements We wish to thank Dr. N. Tanaka and Dr. N. Kobayashi (Department of Gastroenterological Surgery, Transplantation and Surgical Oncology, Okayama University, Okayama, Japan) for their technical help. The work presented in this paper was supported by the National Hi-tech R&D Program of China (No. 2003AA205150) and the Key Technologies R&D Program of China (No. 2004BA706B02-01). References [1] A.O. Shakil D. Kramer G.V. Mazariegos J.J. Fung J. Rakela Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria Liver Transpl 6 2000 163 169 [2] A. Mas J. Rodes Fulminant hepatic failure Lancet 349 1997 1081 1085 [3] R.W. Chapman D. Forman R. Peto R. Smallwood Liver transplantation for acute hepatic failure? Lancet 335 1990 32 35 [4] G. Ostapowicz W.M. Lee Acute hepatic failure: a Western perspective J Gastroenterol Hepatol 15 2000 480 488 [5] B. van Hoek J. de Boer K. Boudjema R. Williams O. Corsmit O.T. Terpstra Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry J Hepatol 30 1999 699 705 [6] S. Miwa Y. Hashikura A. Mita T. Kubota H. Chisuwa Y. Nakazawa Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure Hepatology 30 1999 1521 1526 [7] J.A. Goss C.R. Shackleton M. Maggard K. Swenson P. Seu S.V. McDiarmid Liver transplantation for fulminant hepatic failure in the pediatric patient Arch Surg 133 1998 839 846 [8] C.O. Esquivel E.B. Keeffe G. Garcia J.C. Imperial M.T. Millan H. Monge Resection versus transplantation for hepatocellular carcinoma J Gastroenterol Hepatol 14 1999 S37 S41 [9] A.L. Friedman Why bioartificial liver support remains the Holy Grail ASAIO J 44 1998 241 243 [10] P. Caraceni D.H. Van Thiel Acute liver failure Lancet 345 1995 163 169 [11] S.D. Lidofsky Liver transplantation for fulminant hepatic failure Gastroenterol Clin North Am 22 1993 257 269 [12] R.D. Hughes R. Williams Use of bioartificial and artificial liver support devices Semin Liver Dis 16 1996 435 444 [13] V. Dixit G. Gitnick The bioartificial liver: state-of-the-art Eur J Surg Suppl 1998 71 76 [14] S. Nagamori S. Hasumura T. Matsuura H. Aizaki M. Kawada Developments in bioartificial liver research: concepts, performance, and applications J Gastroenterol 35 2000 493 503 [15] B. Busse J.C. Gerlach Bioreactors for hybrid liver support: historical aspects and novel designs Ann N Y Acad Sci 875 1999 326 339 [16] J.W. Allen T. Hassanein S.N. Bhatia Advances in bioartificial liver devices Hepatology 34 2001 447 455 [17] A.J. Strain J.M. Neuberger A bioartificial liver—state of the art Science 295 2002 1005 1009 [18] N.L. Sussman G.T. Gislason C.A. Conlin J.H. Kelly The Hepatix extracorporeal liver assist device: initial clinical experience Artif Organs 18 1994 390 396 [19] A.A. Demetriou R.S. Brown Jr. R.W. Busuttil J. Fair B.M. McGuire P. Rosenthal Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure Ann Surg 239 2004 660 667 [discussion 667–670] [20] A.J. Ellis R.D. Hughes J.A. Wendon J. Dunne P.G. Langley J.H. Kelly Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure Hepatology 24 1996 1446 1451 [21] F.D. Watanabe C.J. Mullon W.R. Hewitt N. Arkadopoulos E. Kahaku S. Eguchi Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial Ann Surg 225 1997 484 491 discussion 491–484 [22] G.V. Mazariegos D.J. Kramer R.C. Lopez A.O. Shakil A.J. Rosenbloom M. DeVera Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients Asaio J 47 2001 471 475 [23] E. Morsiani P. Pazzi A.C. Puviani M. Brogli L. Valieri P. Gorini Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients Int J Artif Organs 25 2002 192 202 [24] A. Mundt G. Puhl A. Muller I. Sauer C. Muller R. Richard A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support Int J Artif Organs 25 2002 542 548 [25] A. Donini U. Baccarani A. Risaliti A. Degrassi F. Bresadola Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device Am J Gastroenterol 95 2000 1102 1104 [26] M.P. van de Kerkhove E. Di Florio V. Scuderi A. Mancini A. Belli A. Bracco Phase I clinical trial with the AMC-bioartificial liver Int J Artif Organs 25 2002 950 959 [27] P.D. Hay A.R. Veitch M.D. Smith R.B. Cousins J.D. Gaylor Oxygen transfer in a diffusion-limited hollow fiber bioartificial liver Artif Organs 24 2000 278 288 [28] P.D. Hay A.R. Veitch J.D. Gaylor Oxygen transfer in a convection-enhanced hollow fiber bioartificial liver Artif Organs 25 2001 119 130 [29] J.F. Patzer II Oxygen consumption in a hollow fiber bioartificial liver—revisited Artif Organs 28 2004 83 98 [30] M. Shito A.W. Tilles R.G. Tompkins M.L. Yarmush M. Toner Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure J Surg Res 111 2003 53 62 [31] M. Maruyama T. Totsugawa T. Kunieda T. Okitsu N. Shibata M. Takesue Hepatocyte isolation and transplantation in the pig Cell Transplant 12 2003 593 598 [32] K. Kalpana H.S. Ong K.C. Soo S.Y. Tan J. Prema Raj An improved model of galactosamine-induced fulminant hepatic failure in the pig J Surg Res 82 1999 121 130 [33] J.C. Gerlach Long-term liver cell cultures in bioreactors and possible application for liver support Cell Biol Toxicol 13 1997 349 355 [34] L.M. Flendrig J.W. la Soe G.G. Jorning A. Steenbeek O.T. Karlsen W.M. Bovee In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates J Hepatol 26 1997 1379 1392 [35] M.P. van de Kerkhove R. Hoekstra T.M. van Gulik R.A. Chamuleau Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research Biomaterials 25 2004 1613 1625 [36] J. Terblanche R. Hickman Animal models of fulminant hepatic failure Dig Dis Sci 36 1991 770 774 [37] D. Keppler R. Lesch W. Reutter K. Decker Experimental hepatitis induced by D-galactosamine Exp Mol Pathol 9 1968 279 290 [38] A. Medline F. Schaffner H. Popper Ultrastructural features in galactosamine-induced hepatitis Exp Mol Pathol 12 1970 201 211 [39] A.M. Jonker F.W. Dijkhuis F.G. Kroese M.J. Hardonk J. Grond Immunopathology of acute galactosamine hepatitis in rats Hepatology 11 1990 622 627 [40] R. Williams A.E. Gimson Intensive liver care and management of acute hepatic failure Dig Dis Sci 36 1991 820 826 [41] W.R. Ellis P.K. Chu I.M. Murray-Lyon The influence of ammonia and octanoic acid on liver regeneration in the rat Clin Sci (London) 56 1979 95 97 [42] L. Zieve M. Shekleton C. Lyftogt K. Draves Ammonia, octanoate and a mercaptan depress regeneration of normal rat liver after partial hepatectomy Hepatology 5 1985 28 31 [43] J.F. Patzer II G.V. Mazariegos R. Lopez Preclinical evaluation of the Excorp Medical, Inc, Bioartificial Liver Support System J Am Coll Surg 195 2002 299 310 [44] L.M. Flendrig R.A. Chamuleau M.A. Maas J. Daalhuisen B. Hasset C.G. Kilty Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability J Hepatol 30 1999 311 320 [45] T.D. Sielaff M.Y. Hu B. Amiot M.D. Rollins S. Rao B. McGuire Gel-entrapment bioartificial liver therapy in galactosamine hepatitis J Surg Res 59 1995 179 184 [46] V. Cuervas-Mons A. Colas J.A. Rivera E. Prados In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs Transplantation 69 2000 337 344 [47] J. Uchino T. Tsuburaya F. Kumagai T. Hase T. Hamada T. Komai A hybrid bioartificial liver composed of multiplated hepatocyte monolayers ASAIO Trans 34 1988 972 977 [48] J. Rozga F. Williams M.S. Ro D.F. Neuzil T.D. Giorgio G. Backfisch Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells Hepatology 17 1993 258 265 [49] J. Rozga M.D. Holzman M.S. Ro D.W. Griffin D.F. Neuzil T. Giorgio Development of a hybrid bioartificial liver Ann Surg 217 1993 502 509 discussion 509–511 [50] L.M. Flendrig F. Calise E. Di Florio A. Mancini A. Ceriello W. Santaniello Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver Int J Artif Organs 22 1999 701 709 [51] J. Tsiaoussis P.N. Newsome L.J. Nelson P.C. Hayes J.N. Plevris Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl 7 2001 2 10 [52] D.C. Mears G. Stewart J. Sun K. Woodman R. Bourne L. Wang Experience with a porcine hepatocyte-based bioartificial liver support system Transplant Proc 35 2003 441 442 [53] U. Martin M.E. Winkler M. Id H. Radeke L. Arseniev Y. Takeuchi Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV) Xenotransplantation 7 2000 138 142 [54] C. Patience Y. Takeuchi R.A. Weiss Infection of human cells by an endogenous retrovirus of pigs Nat Med 3 1997 282 286 [55] R. Kuddus J.F. Patzer R. Lopez G.V. Mazariegos B. Meighen D.J. Kramer Valuation of transmission of porcine endogenous retrovirus into patients subjected to hemoperfusion using an extracorporeal bioartificial liver support system Transplant Proc 33 2001 1976 [56] E. Falasca V. Adami G. Astori A. Donini F. Biffoni A. Degrassi Porcine endogenous retrovirus does not infect human cells using a bioartificial liver model system Transplant Proc 33 2001 1780 1781